Rhythm Pharmaceuticals RYTM Cash Flow Statement (2016-2026)

NASDAQ RYTM
$113.66 -0.28 (-0.25%)
As of: Nov 10, 2026 · 12:17 PM EST
Reported Financials

Rhythm Pharmaceuticals Quarterly Cash Flow Statement

Periods 41 quarters
Latest Sep 2026

Rhythm Pharmaceuticals reported cash from operations of -$3.06M and free cash flow of -$3.06M for the quarter ended Sep 2026, up 88.5% year over year. This cash flow statement covers 41 quarters of results from Sep 2016 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Operating Activities
Net Income
-42.87M-52.76M-45.00M-40.86M-42.49M-52.18M-46.70M-44.16M-41.63M-141.37M-32.26M-43.68M-43.29M-49.50M-46.63M-52.90M-47.51M-55.64M-49.30M-41.37M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
2.14M3.20M3.06M3.13M3.15M4.02M4.01M
Depreciation & Amortization (CF)Dep. & Amort.
Share-based CompensationStock Comp.
4.68M4.61M5.14M4.80M5.29M6.38M8.89M8.61M8.67M7.77M10.36M11.00M10.56M12.86M15.88M18.81M19.27M23.10M26.06M25.03M
Deferred Taxes
Gains from Sales and DivestituresGains Divest
Gains from Investment SecuritiesGains Investment
0.24M8.90M
Other non-cash itemsOther Non-Cash
-0.07M-0.07M-0.07M-0.07M5.07M0.04M6.32M3.12M4.09M3.63M5.68M4.84M5.44M5.60M3.71M5.76M5.12M6.60M4.31M4.40M
Change in Working Capital
Change in ReceivablesChange Receivables
0.60M2.90M1.89M5.71M0.71M0.33M-0.17M2.90M1.71M-0.79M-0.69M7.83M6.60M-6.18M8.11M6.22M-1.29M
Change in InventoryChange Inventory
-0.01M1.23M2.57M0.69M1.59M0.86M-0.12M3.49M1.90M4.85M0.58M-0.48M2.45M4.93M3.09M2.34M0.75M
Change in Accrued ExpensesChange Accrued Exp.
12.92M-0.05M-1.55M-12.57M15.71M5.17M0.66M4.09M4.86M-1.25M0.48M7.51M15.18M-3.63M13.26M11.02M1.26M-5.62M16.46M12.87M
Change in Other Operating AssetsOther Assets Change
6.21M5.71M-4.45M0.77M2.31M-2.06M-0.61M3.37M-5.24M1.23M-3.76M-0.80M0.92M3.10M1.38M-1.14M3.39M0.05M-2.80M3.79M
Change in Other Operating LiabilitiesOther Liabilities Change
-0.55M-7.08M-0.01M-0.14M-1.29M0.19M-0.15M-0.05M
Other Working Capital ChangesOther WC Changes
-6.21M-5.71M4.45M-1.32M-9.39M2.05M0.47M-3.37M5.24M-1.23M3.76M0.80M-0.92M-4.39M-1.38M1.14M-3.19M-0.20M2.76M-3.79M
Cash from OperationsCash from Ops.
-40.47M-53.63M-38.81M-46.99M-34.00M-36.43M-41.09M-29.25M-29.38M-40.74M-29.08M-25.22M-18.85M-40.35M-23.31M-26.62M-25.39M-44.19M-9.15M-3.06M
Investing Activities
Capital ExpendituresCapex
0.07M0.13M0.06M0.10M0.00M0.05M0.00M0.00M0.95M
Change in Property, Plant and EquipmentChange in PP&E
-0.07M-0.13M-0.06M-0.10M0.00M-0.05M0.00M0.00M-0.95M
Change in IntangiblesChange Intangibless
4.52M0.88M0.27M40.00M0.50M
Purchase of InvestmentsInvestments Purchased
68.73M39.48M10.96M101.08M100.42M69.64M75.43M169.19M40.65M135.62M66.38M33.52M26.95M267.85M20.35M42.20M43.49M90.99M
Sale and Maturity of InvestmentsInvestments Sold
69.05M112.13M51.00M61.48M59.64M92.68M124.50M74.50M63.29M70.05M57.75M45.31M87.54M58.33M80.99M61.50M51.65M99.25M57.50M75.38M
Other Investing Activities (as filed)Other investing (as filed)
Cash from Investing ActivitiesCash from Investing
7.25M72.52M35.98M-39.70M-40.78M18.46M48.19M-94.96M22.64M30.05M-8.56M-90.82M21.16M24.81M54.04M-246.35M30.35M57.05M14.01M-16.11M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
37.50M-2.66M
Long-Term Debt RepaymentsLT Debt Repayment
1.35M1.31M2.17M2.57M2.78M2.97M3.34M3.81M4.62M4.33M5.57M5.40M4.29M6.91M7.93M
Net Long-Term Debt Issued (Repaid)Net LT Debt
37.50M-2.66M-1.35M-1.31M-2.17M-2.57M-2.78M-2.97M-3.34M-3.81M-4.62M-4.33M-5.57M-5.40M-4.29M-6.91M-7.93M
Net Debt Issuances and RepaymentsNet Debt Issuance
37.50M-2.66M-1.35M-1.31M-2.17M-2.57M-2.78M-2.97M-3.34M-3.81M-4.62M-4.33M-5.57M-5.40M-4.29M-6.91M-7.93M
Change in Capital Stock
Common Stock IssuedStock Issued
0.10M0.40M121.06M20.03M1.22M0.34M50.84M5.00M7.03M1.40M5.83M42.14M37.11M3.44M-27.82M225.14M7.35M7.00M7.65M
Net Shares Issued and RepurchasedNet Shares Issued
0.10M0.40M121.06M20.03M1.22M0.34M50.84M5.00M7.03M1.40M5.83M42.14M37.11M3.44M-27.82M225.14M7.35M7.00M7.65M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
0.10M0.40M121.06M20.03M1.22M0.34M50.84M5.00M7.03M1.40M5.83M42.14M37.11M3.44M-27.82M225.14M7.35M7.00M7.65M
Other financing activities (as filed)
-8.46M-1.26M-4.51M
Cash from Financing ActivitiesCash from Financing
0.10M0.40M37.50M158.56M17.37M-0.13M-0.97M73.04M2.42M4.24M146.18M2.49M38.33M32.50M-0.89M189.30M-2.95M-5.40M-1.17M-6.25M
Additional items
Exchange Rate EffectFX Effect
0.09M-0.11M0.08M-0.19M-0.07M-0.30M-0.60M0.98M0.00M-0.28M0.30M0.06M0.45M-0.22M0.46M
Change in Cash
-33.12M19.29M34.67M71.88M-57.41M-18.02M6.02M-51.09M-4.51M-6.52M108.24M-114.15M41.62M16.96M29.55M-83.36M2.07M7.92M3.48M-24.96M
Ending Cash Balance
59.58M78.87M113.54M185.42M128.01M109.99M116.01M64.92M60.41M53.89M162.13M47.98M89.60M106.56M136.11M52.75M54.82M62.74M66.22M41.26M
Free Cash FlowFCF
-40.54M-53.76M-38.87M-47.08M-34.00M-36.48M-41.09M-29.25M-29.38M-40.74M-29.08M-25.22M-18.85M-40.35M-23.31M-26.62M-25.39M-44.19M-9.15M-3.06M
Net Cash FlowNCF
-33.12M19.29M34.67M71.88M-57.41M-18.10M6.14M-51.17M-4.32M-6.45M108.54M-113.54M40.64M16.96M29.83M-83.67M2.01M7.47M3.70M-25.42M

Rhythm Pharmaceuticals Cash Flow Statement API

Pull Rhythm Pharmaceuticals's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=RYTM&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY